Stockreport

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiati...

Cel-Sci Corporation  (CVM) 
NASDAQ:AMEX Investor Relations: cel-sci.com/investor_relations.html
PDF ratio of 0.27) are the strongest Multikine efficacy results reported to date, reflecting results in patients who met the CEL-SCI confirmatory Registration Study target p [Read more]